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Abstract This paper assesses the influence of a number of factors taken into account when a 
brand name drug is replaced by a generic one. It also evaluates responses of health 
professionals – physicians and pharmacist—and patients regarding the issue of 
switching. We compared and contrasted their responses in order to identify new points 
of cooperation for the intended benefit of the patient. Thus, the sample drew from all 
three groups, consisting of 50 doctors, 50 pharmacists, and 50 patients. We collected 
information regarding the age, residence, income level, and education level for the 
patients, and age and experience for the specialists. Based on responses to the survey, 
replacing the original medication with a generic one raises many issues, such as lack of 
information for the patient and specialist, lack of collaboration between physician and 
pharmacist, ineffective communication between specialist and patient, and the influence 
of the overall profit motive. 
   
  












Highlights ✓ This paper concludes that the switch between original medication with a generic one is 
rather a necessity than an option. 
✓ The pharmaceutical market is currently confronted with some deficiencies related to 
information and/ or collaboration between physicians, pharmacists and patients. 
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Introduction 
The prescribing, dispensing, and purchasing of 
drugs are influenced by many factors, and sometimes 
attempts to find the best approach can affect the 
relationship between physician/pharmacist and patient, 
the one who should be the primary beneficiary of health 
services (1). 
The switch from brand name to generic medication 
is increasingly encountered in the current, fluctuating 
pharmaceutical environment, one that is continuously 
changing due to changing economic and social 
conditions. At the same time, many original medications 
have lost their patent/license, with a consequential 
disappearance of the original medication and increased 
reliance upon generic drugs (2).  
The original formulation is initially discovered and 
developed by a pharmaceutical company, and once 
approved for marketing, the company can market and 
sell the “original” product exclusively under patent to 
recoup funds for research and development and to net 
profit.(3). Current studies estimate that bringing a new 
drug to market incurs an average cost of 802 million US 
dollars over a period of 10 to 15 years (2, 3).  
Once the license for a particular product expires, it 
is eligible for conversion into a “generic medicine.” 
Because the generic drug may differ in color, taste, 
shape, inactive ingredients, preservatives, and/ or 
packaging, generic manufacturers are usually required 
to submit additional documents to the regulating 
authority to demonstrate that their drug is manufactured 
in compliance with good manufacturing practice, that it 
is as pure and stable as the original drug, and that 
bioequivalence tests show the same pharmacokinetic 
parameters within the body, that is, it must dissolve and 
be absorbed at the same rate and to the same extent as 
the original product. Specifically, the generic form must 
act the same as the patented drug via the same 
mechanism, and it must also follow the same pattern of 
absorption, distribution, metabolism, and elimination 
from the body (3, 4).  
However, replacing the original drug with a generic 
form is a difficult choice, in some cases, for both the 
physician and patient, on the assumption that the generic 
drug may not offer the same quality as the original 
preparation, as reflected by its lower price. The lower 
price, of course, is explained by the fact that the 
manufacturer of the generic drug requires no investment 
in clinical research and marketing of the new product. In 
addition, the fact that many pharmaceutical companies 
produce generics leads to competition and lower prices 
(3). At times, patients complain of increased incidence 
of side effects when switching to a generic drug, and 
therapeutic ineffectiveness is often reported by patients 
to the physician or the pharmacist. However, the lack of 
pharmacovigilance reports and an increased number of 
research studies demonstrate no significant differences 
in the effectiveness of generic medicines (5, 6).        
Ongoing information regarding the comparison of 
original and generic drugs is essential for physicians 
when choosing to prescribe either the generic vs the 
brand name medication, as the physician can take into 
account the therapeutic effectiveness/ineffectiveness 
and safety profile of each (6). A better understanding of 
issues facing the pharmaceutical market, including the 
unavailability of the original brand name medications, 
and ongoing collaboration between physician and 
pharmacist could mitigate patient concern about 
acquiring the recommended drug. Other issues such as 
stabilizing the patient with a particular treatment, 
ensuring adherence to the prescribed medication, and 
consideration of the patient’s financial situation should 
not be neglected. However, campaigns conducted to 
promote various generic drugs, along with close 
relationships between the physician/pharmacist and 
medical representative, could result in the use of 
medications that are not optimal for treating the patient's 
needs (7, 8).      
Pharmacists are the final link in the chain requiring 
well-regulated drug dispensing rules, but the current 
financial problems (delayed payments by the National 
Health Insurance House or the pharmacy economic 
profit) may compromise ethics (1). For example, 
patients’ access to information about medicines through 
media and their financial limitations may lead them to 
pressure their pharmacist, frequently requesting certain 
drugs without first consulting with their physician or 
health specialist (9).   
The aim of this study was the quantitative analysis 
of the responses of health professionals—physicians and 
pharmacists—and patients on factors that influence the 
switch from an original medication to a generic one. We 
also conducted a comparative analysis of the responses 
of patients, physicians, and pharmacists with the hope of 
improving the relationships among these three groups so 
as to obtain greater benefit for the patient.  
Materials and Methods 
The study was conducted in Bucharest and the 
surrounding vicinity between January 2016 and May 
2016 by distributing questionnaires about generic and 
brand name drugs to healthcare professionals and the 
non-healthcare general public. The sample included 
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three groups: 50 doctors, 50 pharmacists, and 50 
patients, taking into account various inclusion and 
exclusion criteria (Table I). 
Patients Healthcare professionals 
Inclusion criteria Inclusion criteria 
- Age over 18 
- Romanian citizen 
- People who wanted 
to take part in this 
study 
- People that are practicing 
their job (physicians and 
pharmacists) 
- People who are practicing 
medicine in Bucharest or 
the counties/ cities/towns 
nearby 
- People who wanted to take 
part in this study 
Exclusion criteria Exclusion criteria 
- Psychiatric disorders 
that do not allow the 
proper filling of the 
questionnaire 
- Illiteracy 
- People who did not 
want to take part in 
this research 
- People who did not want to 
take part in this research 
- People who do not practice 
their profession even if they 
have specialized studies 
Table I. Criteria for inclusion and exclusion for 
the sample in this research 
 
The instruments were three different 
questionnaires, one for each type of participant: 
physician, pharmacist, and patient.  
Fifty patients completed a questionnaire which 
collected information about age, residence, education 
level, and income level, along with 8 additional items 
used to assess patient behavior. These included: 
1. The difference between original and generic drug (if 
they did not know, they were informed when given the 
questionnaire). 
2. The observed differences in health status after 
switching from the original drug to the generic one. 
3. The effective use of generic drugs in their treatment. 
4. The primary source of information to be taken into 
account when purchasing medication. 
5. The importance of medical advice when buying 
medicine. 
6. The influence of the drug’s cost when choosing 
between an original and generic medication. 
7. The problem of failing to purchase a specific drug that 
the patient is using in their treatment. 
8. Whether the switch from the original prescription to 
the generic one is based on the recommendation of the 
specialists or on other sources of information. 
Fifty physicians were included in this research. 
In addition to information about age, experience, and 
type of speciality (medical or surgical), eight items were 
used to assess their behavior: 
1. The differences between an original drug and a 
generic one. 
2. The therapeutic efficacy and incidence of adverse 
reactions of the original vs. generic drug. 
3. The safety profile of a generic drug. 
4. The previous medicines given to their patients and 
their efficacy. 
5. The financial situation of the patient and guidance to 
use generic drugs. 
6. The relationship with the medical representative and 
its influence when choosing to prescribe a certain 
medication. 
7. The cooperation with the pharmacist when specifying 
or switching from the original drug to the generic one 
and their knowledge about the lack of medicines in the 
market. 
8. The previous experience concerning patient attitudes 
regarding the use of the generic drug. 
Finally, 50 pharmacists completed a 
questionnaire. In addition to age and experience, seven 
items were taken into account to assess their attitudes. 
1. The differences between an original drug and a 
generic one. 
2. The therapeutic efficacy and incidence of adverse 
reactions of the original vs. generic drug. 
3. Previous experience concerning the patient's 
preferences regarding the use of an original vs. generic 
drug. 
4. The importance of the physician's recommendation 
when dispensing the medical prescription and the 
previous treatment received by the patient and its 
efficacy. 
5. The influence of the patient's financial situation when 
administering the original medicine and their counseling 
on alternatives to original medicines. 
6. The relationship between the medical representative 
and the pharmacy’s financial profit, and influence of 
these factors on drug release. 
7. The lack of original drugs in the pharmaceutical 
market, the impact of this lack, and how the relationship 
between the pharmacist and the patient is affected. 
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Results 
The quantitative analysis of the answers given by 
the evaluated people    
The patients who answered this questionnaire were 
24 to 73 years old (average = 38 years), predominantly 
living in an urban environment (84.3%), with a monthly 
income between 1000-2000 lei (51%). 64.7% were 
university graduates, 17.6% high school graduates, 
15.7% postgraduate degree holders, and only 2% college 
graduates. Of the total patients, 83.7% knew the 
difference between original and generic drugs, and 60% 
considered that significant differences appear after 
switching from the original drug. 65.3% of patients 
found that the generic drug was not as effective as the 
brand name drug. 83.7% believed the physician to be the 
most important source of information, 51% the 
pharmacist, 8.2% other people’s recommendations, 
whereas only 2% were influenced by media. Most 
patients heeded the guidance the physician's orders 
much (50%) to very much (48%), and only 2% of them 
less. Patients also considered that the cost of the original 
drug was an essential factor when choosing between 
original drug and generic drug (58.3%), 54% had 
experienced at least once a problem with the purchase of 
an original drug and 46% had ever encountered such a 
situation. 64.3% indicated that the switch from the 
original drug to a generic one was influenced by 
pharmacists, 25% by physicians, and 10.7% by other 
factors not related to specialists.    
The physicians who participated were 25 to 50 
years old (average = 32 years), with experience in the 
medical field of less than a year (23.1%), between 1 and 
5 years (38.5%), 5-10 years (7.7%) and 10 years or more 
(30.8%). Their speciality was medical for 84.6% and 
surgical for 15.4%. All physicians were familiar with the 
concepts of original vs. generic drug and the differences 
between them. According to physicians, there are 
differences between therapeutic efficacy and incidence 
of side effects of the original vs. generic drug, 53.8% of 
them responding positively to this item. Also, 61.5% 
believed that the original medicine presents a better 
safety profile. All physicians took into account the 
treatment previously administered to the patient and its 
efficacy, but 53.8% did not take into account the 
patient’s financial situation when prescribing a new 
medicine. Regarding previous experience, 69.2% 
answered that patients were reluctant to use the generic 
medicine. 76.9% responded that their relationship with 
a medical representative did not influence their 
prescribing, but 23.1% indicated this as very important. 
38.5% of the physicians cooperated with the pharmacist 
when they prescribed a patented drug or a generic one, 
but a significant percentage of 61.5% did not have any 
connections with the pharmacist. 62.5% of the 
physicians were aware of the lack of original medicines 
in the pharmaceutical marketplace, but this did not 
influence them to prescribe generic drugs. 
Pharmacists were 24 to 50 years old (average = 28 
years), with experience in the pharmaceutical field 
mostly between 1 to 5 years (44.9%) or less than one 
year (40.8%).  Pharmacists understood the concepts of 
original and generic drug and the differences between 
them. According to 89.9 % pharmacists, there are 
differences between the therapeutic efficacy and 
incidence of side effects for the original vs. generic drug. 
Regarding previous experience, 67.3% of pharmacists 
noted that patients prefer the original drug. All surveyed 
pharmacists advised patients on alternatives to the 
original drugs, but 20.4% did not consider the 
recommendations made by the patient’s physician. 
95.9% of pharmacists took into account the financial 
situation of the patient, and they guided them to 
alternatives that they could afford. The previous 
treatment used by the patient and its efficacy were 
important factors that 98% of the pharmacists 
considered when dispensing the medical prescription. 
The decision when choosing between an original or 
generic medicine was influenced by the relationship 
between the medical representative and the pharmacy’s 
financial profit only for 18.8% of the pharmacists, while 
81.2% ignored this aspect. 51% of pharmacists believed 
that the lack of original drugs in the pharmaceutical 
market affected their relationship with the patient, 
20.4% very much, 20.4% little and 8.2% very little. 
Discussions 
Comparative analysis of the responses across the 
three groups 
The surveyed patients lived predominantly in urban 
areas. Most were university graduates, a fact that reflects 
their knowledge about original vs. generic medications, 
as well as their better information about the available 
alternatives in the pharmaceutical market. Patients were 
concerned about the cost difference between original 
and generic medications, believing that generic drugs 
were less effective than patented medicine and leading 
to a higher frequency of complaints regarding side 
effects. This idea was further supported by physicians 
and pharmacists who were not always well informed 
about current bioequivalence studies, with both groups 
believing significant differences exist between the two 
types of drugs, with patented medicines having a better 
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safety profile than the generic equivalent. Such concerns 
by physicians and pharmacists resulted in patients’ 
reluctance to use a generic drug. Patients were 
influenced by the price of drugs, leading them to choose 
a generic medicine even when not convinced their 
choice was the best option. While this factor was very 
important to patients, physicians did not take into 
account financial implications when prescribing 
medicine, as they, along with pharmacists, generally 
believe the original drug to be more effective (10). 
Although the main sources of information for the patient 
were the physician and the pharmacist, a significant 
percentage took into account recommendations made by 
other people or by the media (11, 12). Such information 
may be inaccurate and could result in pressure on the 
physician or pharmacist to presribe less appropriate 
medication for the patient’s particular pathology (13, 14, 
15). From our results, both physicians and pharmacists 
took into account the treatment previously used by the 
patient and their adherence to the treatment, the fact that 
brings a real benefit for the patient, especially since, as 
shown in this study, patients generally listen to the 
physician's advice (15).  
Lack of original medicines in the current 
pharmaceutical market was a concern for all three 
groups evaluated (16, 17). Although physicians were 
informed about unavailable products, the lack of 
collaboration with the pharmacist may result in the 
physician’s prescribing a less desired medication, and 
thus a significant number of patients face the problem of 
being able to afford their treatment. As difficulty 
acquiring their medication increases, the patients may 
become less confident in the services of the pharmacist. 
Pharmacists responded to this dilemma, indicating it can 
seriously affect their relationship and collaboration with 
the patient (18). Pharmacists advised their patients about 
alternatives to the original medicines, and a 
representative percentage took into account the 
recommendations of the physician (18, 19). Given that 
most surveyed patients reported that the switch from an 
original drug to a generic was made on the 
recommendation of the pharmacists, and given that 
pharmacists generally do not collaborate with 
physicians, the patient-physician relationship is likely to 
be affected (20, 21).  
Conclusions 
This study presents some of the factors that 
influence the substitution of an original medication with 
a generic one. This paper concludes that this switch is 
often not an option, but rather a necessity. The study also 
highlights the problems that the pharmaceutical market 
is now facing, such as a lack of information for both 
patient and specialists, the lack of collaboration between 
physician and pharmacist, ineffective communication 
between specialists and patients, and even sometimes 
the financial benefits to health care professionals that 
places the needs of the patients as secondary when in 
fact, they should be the primary beneficiaries of 
healthcare services.  
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